GSK

This study tests whether giving the immunotherapy drug dostarlimab for a longer period can completely eliminate tumors in people with a specific genetic type of rectal cancer. Participants have stage II or III rectal cancer that is mismatch repair deficient (dMMR) or microsatelli…

This study follows up on African children who received an experimental Shigella vaccine in earlier studies. Researchers will take blood samples 1, 2, and 3 years after the last vaccine dose to see how long the immune protection lasts. No new vaccines are given in this study. The …

This early-phase study is testing a combination of two experimental drugs, Ris-Rez and ivonescimab, in about 184 adults with advanced solid tumors that have spread. The main goals are to find a safe dose, understand side effects, and see if the combo can shrink tumors. It's a fir…

This phase 3 trial tests whether risvutatug rezetecan, an antibody-drug conjugate that delivers a toxin directly to prostate cancer cells, can slow or shrink tumors better than standard hormone therapy. About 684 men with metastatic castration-resistant prostate cancer will recei…

This phase 3 trial tests whether a new drug called mocertatug rezetecan (Mo-Rez) combined with bevacizumab works better than standard chemotherapy plus bevacizumab for women with platinum-sensitive ovarian cancer. The study includes about 690 participants whose cancer has returne…

This phase 3 trial tests whether adding an experimental drug (GSK5733584) to standard immunotherapy can help keep advanced or recurrent endometrial cancer from growing. About 610 adults who have already completed initial chemotherapy with immunotherapy will receive either the new…

This early-stage trial asks whether ganfeborole, an experimental tuberculosis drug, changes how the body processes an oral contraceptive containing ethinyl estradiol and levonorgestrel. Healthy women aged 18 to 65 who cannot become pregnant will take the contraceptive alone and t…

This phase 3 trial is testing whether an experimental drug called felcorekibart, when added to standard asthma care, can reduce the number of severe asthma attacks in adults and adolescents whose asthma is not well controlled. Participants will receive either felcorekibart or a p…

This phase 3 trial tests whether the experimental drug felcorekibart, added to standard care, can reduce nasal polyps and improve symptoms like nasal blockage and loss of smell in adults with chronic rhinosinusitis with nasal polyps. Participants receive either felcorekibart or a…

This phase 3 trial tests whether an experimental drug called felcorekibart can reduce nasal polyps and improve symptoms like nasal blockage and loss of smell in adults with chronic rhinosinusitis with nasal polyps. Participants receive either felcorekibart or a placebo on top of …

This phase 3 trial is testing whether an investigational drug called felcorekibart, when added to standard asthma care, can reduce the number of serious asthma attacks in adults and adolescents (ages 12-80) whose asthma is not well controlled. Participants will receive either fel…

This clinical trial is testing whether an investigational drug called felcorekibart, when added to standard COPD therapy, can reduce the number of moderate and severe flare-ups in adults aged 40 to 80 with moderate to very severe COPD. Participants will receive either felcorekiba…

This phase 3 trial tests whether the experimental drug mocertatug rezetecan (Mo-Rez), given alone or with bevacizumab, can delay cancer progression better than standard observation or bevacizumab alone in people with newly diagnosed advanced ovarian cancer that does not have a ho…

This early-stage trial is testing whether a drug called aletekitug is safe and tolerable for people with moderate to severe ulcerative colitis, a chronic inflammatory bowel disease. The drug works by blocking a protein called IL-18, which may play a role in the inflammation that …

This early trial is testing an experimental biologic drug called aletekitug in adults with moderate to severe ulcerative colitis. The main goal is to see if the drug is safe and tolerable when given repeatedly. Researchers will monitor side effects and changes in lab tests, vital…

This trial is testing whether belantamab, a drug used for multiple myeloma, can be given as a quick injection under the skin instead of a slow drip into a vein. About 22 adults with multiple myeloma who are already on standard maintenance therapy will receive both forms in a cros…

This study investigates whether two common vaccines—the shingles vaccine (RZV) and an RSV vaccine (RSVPreF3)—can slow the buildup of fatty plaque in the coronary arteries. The trial enrolls adults aged 50 and older who are at risk for cardiovascular events. Participants receive e…

This early-stage study tests a new pneumococcal vaccine (Pn-MAPS30plus) in 60 healthy infants to see if it is safe and what side effects it may cause. Babies will receive three doses starting around 2 months old, followed by a booster at 12-15 months. The study compares the new v…

This phase 2 study tests a new antimalarial drug called GSK3772701 in 70 adults with uncomplicated P. falciparum malaria. Participants receive different doses for 1 to 3 days to see if it is safe and clears the parasite. The goal is to find a new treatment option that could work …

This phase 2 trial is testing whether different dosing schedules of belantamab mafodotin, when combined with bortezomib and dexamethasone, can reduce the risk of serious eye problems while still controlling multiple myeloma. About 150 adults with relapsed or refractory multiple m…

This early-stage trial tests a new drug called GSK5926371 in about 49 adults with B-cell non-Hodgkin lymphoma that has returned or not responded to at least two prior treatments. The main goals are to check the drug's safety and see if it can shrink tumors. Researchers will also …

This study tests the safety of the immunotherapy drug dostarlimab when given together with standard chemotherapy (carboplatin and paclitaxel) as a first treatment for adults in India with advanced or recurrent endometrial cancer. Participants receive the drug combination initiall…

This study tests a drug called momelotinib in 136 adults with VEXAS syndrome, a rare inflammatory disease caused by a genetic mutation. The goal is to see if the drug can reduce disease activity, with participants receiving either momelotinib or a placebo. This is a phase 2/3 tri…

This study tests an investigational vaccine that combines protection against measles, mumps, rubella, and chickenpox (varicella) in a single shot. It will be given as a second dose to healthy children aged 4 to 6 years who have already received a first dose of a similar vaccine. …

This early-stage study tests a new antibody drug (GSK4425689A) designed to prevent malaria. Researchers will give the drug to 40 healthy adults either through an IV or a shot under the skin to check for side effects and how the body processes it. The goal is to see if it is safe …

This study checks if a new propellant (HFA-152a) in asthma inhalers is as safe as the current one (HFA-134a). About 110 adults with asthma will use both types of inhalers and be monitored for side effects. The goal is to make sure the new propellant is safe for everyday use.

This study measures how much of the antibiotic gepotidacin passes into breast milk after a single 3000 mg dose. Eight healthy lactating women will provide milk and blood samples over 72 hours. The goal is to understand drug exposure for nursing infants, which could guide future u…

This early-phase study looks at how the drug combination BVd (belantamab mafodotin, bortezomib, and dexamethasone) is processed by the body in people with multiple myeloma who also have moderate liver problems. About 20 participants will be enrolled to compare drug levels and saf…

This early-phase trial will test a single dose of the experimental drug GSK4771261 in 30 healthy adults of Chinese, Japanese, and White/European backgrounds. The main goal is to check safety, how the body processes the drug, and whether it causes an immune response. No treatment …

This early-stage study will give a single dose of the experimental antibiotic gepotidacin to 20 hospitalized children aged 2 to 12 who are already receiving standard antibiotics for a bacterial infection or as a preventive measure. Researchers will measure how the drug moves thro…